The FDA setback highlights ongoing tensions between patient needs, regulatory processes, and the use of real-world evidence in evaluating treatments for rare diseases
The safety profile in alopecia areata was generally consistent with that in approved indications, and no new safety signals were identified in this study
The average baseline SALT score was 83.8, indicating about 16% scalp hair coverage
Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,
Mamilli last held the role of Chief Digital & Technology Officer and Group President for China, Brazil and Precision Animal Health at Zoetis
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
Partnership to supercharge LVMH Recherche with Integrated Biosciences’ innovative AI and synthetic biology platform for targeting skin aging
Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer
Buckley served as Chairman and Chief Executive Officer at Vanguard from 2018 until his retirement in 2024
Finerenone is the first mineralocorticoid receptor (MR) antagonist to demonstrate definitive cardiovascular benefits in a Phase III study in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ?40%
Subscribe To Our Newsletter & Stay Updated
